Anja Ebert

Anja Ebert

Auto-generated profile, based on publicly available information

Anja Ebert

Department of Molecular Biology and Genetics, Aarhus University, Universitetsbyen 83, 8000 Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2018 in Science
Verified
Journal Article
Closed access
PDF file
MMMatthias Muhar
Matthias Muhar
AEAnja Ebert
Anja Ebert
TNTobias Neumann
Tobias Neumann
CUChristian Umkehrer
Christian Umkehrer
JJJulian Jude
Julian Jude
JZJohannes Zuber
Johannes Zuber
Profiling transcription—a SLAM dunk: Identification of the direct target genes of transcription factors could shed light on how healthy cells become malignant. Muhar et al. applied a modified version of a transcript-mapping method called SLAM-seq to identify the target genes of two transcriptional regulators of major interest in cancer research (see the Perspective by Sabò and Amati). The MYC oncoprotein selectively activates transcription of just a few genes, primarily those involved in basic cell metabolism. In contrast, BRD4, a bromodomain-containing protein that is being targeted for cancer therapy, activates transcription of many genes. Science , this issue p. 800 ; see also p. 713

1 July 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LHLouisa Hill
Louisa Hill
AEAnja Ebert
Anja Ebert
MJMarkus Jaritz
Markus Jaritz
GWGordana Wutz
Gordana Wutz
KNKota Nagasaka
Kota Nagasaka
MBMeinrad Busslinger
Meinrad Busslinger

29 July 2021 in Science Immunology
Verified
Journal Article
Closed access
LCLesly Calderón
Lesly Calderón
KSKarina Schindler
Karina Schindler
SMStephen Malin
Stephen Malin
ASAlexandra Schebesta
Alexandra Schebesta
QSQiong Sun
Qiong Sun
MBMeinrad Busslinger
Meinrad Busslinger
Pax5 controls the generation, proliferation, and survival of all mature B cells by promoting PI3K signaling via PTEN down-regulation.

2 February 2023 in Blood
Verified
Journal Article
Closed access
PDF file
JSJohannes Schmoellerl
Johannes Schmoellerl
IBInês A. M. Barbosa
Inês A. M. Barbosa
MMMartina Minnich
Martina Minnich
FAFlorian Andersch
Florian Andersch
LSLeonie Smeenk
Leonie Smeenk
JZJohannes Zuber
Johannes Zuber
Chromosomal rearrangements involving the MDS1 and EVI1 complex locus (MECOM) on chromosome 3q26 define an aggressive subtype of acute myeloid leukemia (AML) that is associated with chemotherapy resistance and dismal prognosis. Established treatment regimens commonly fail in these patients, therefore, there is an urgent need for new therapeutic concepts that will require a better understanding of the molecular and cellular functions of the ecotropic viral integration site 1 (EVI1) oncogene. To characterize gene regulatory functions of EVI1 and associated dependencies in AML, we developed experimentally tractable human and murine disease models, investigated the transcriptional consequences of EVI1 withdrawal in vitro and in vivo, and performed the first genome-wide CRISPR screens in EVI1-dependent AML. By integrating conserved transcriptional targets with genetic dependency data, we identified and characterized the ETS transcription factor ERG as a direct transcriptional target of EVI1 that is aberrantly expressed and selectively required in both human and murine EVI1–driven AML. EVI1 controls the expression of ERG and occupies a conserved intragenic enhancer region in AML cell lines and samples from patients with primary AML. Suppression of ERG induces terminal differentiation of EVI1-driven AML cells, whereas ectopic expression of ERG abrogates their dependence on EVI1, indicating that the major oncogenic functions of EVI1 are mediated through aberrant transcriptional activation of ERG. Interfering with this regulatory axis may provide entry points for the development of rational targeted therapies.

12 May 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
LSLeonie Smeenk
Leonie Smeenk
SOSophie Ottema
Sophie Ottema
RMRoger Mulet-Lazaro
Roger Mulet-Lazaro
AEAnja Ebert
Anja Ebert
MHMarije Havermans
Marije Havermans
RDRuud Delwel
Ruud Delwel
In acute myeloid leukemia (AML) with inv(3)(q21;q26) or t(3;3)(q21;q26), a translocated GATA2 enhancer drives oncogenic expression of EVI1. We generated an EVI1-GFP AML model and applied an unbiased CRISPR/Cas9 enhancer scan to uncover sequence motifs essential for EVI1 transcription. Using this approach, we pinpointed a single regulatory element in the translocated GATA2 enhancer that is critically required for aberrant EVI1 expression. This element contained a DNA-binding motif for the transcription factor MYB, which specifically occupied this site at the translocated allele and was dispensable for GATA2 expression. MYB knockout as well as peptidomimetic blockade of CBP/p300-dependent MYB functions resulted in downregulation of EVI1 but not of GATA2. Targeting MYB or mutating its DNA-binding motif within the GATA2 enhancer resulted in myeloid differentiation and cell death, suggesting that interference with MYB-driven EVI1 transcription provides a potential entry point for therapy of inv(3)/t(3;3) AMLs.Significance: We show a novel paradigm in which chromosomal aberrations reveal critical regulatory elements that are nonfunctional at their endogenous locus. This knowledge provides a rationale to develop new compounds to selectively interfere with oncogenic enhancer activity.This article is highlighted in the In This Issue feature, p. 2659

24 April 2025 in The EMBO Journal
Verified
Journal Article
Open access
SRSebastian Riedelbauch
Sebastian Riedelbauch
SMSarah Masser
Sarah Masser
SFSandra Fasching
Sandra Fasching
SLSung-Ya Lin
Sung-Ya Lin
HSHarpreet Kaur Salgania
Harpreet Kaur Salgania
PAPeter Andersen
Peter Andersen
Despite being essential for fertility, genome-defense-pathway genes often evolve rapidly. However, little is known about the molecular basis of this adaptation. Here, we characterized the evolution of a protein interaction network within the PIWI-interacting small RNA (piRNA) genome-defense pathway in Drosophila at unprecedented scale and evolutionary resolution. We uncovered the pervasive rapid evolution of a protein interaction network anchored at the heterochromatin protein 1 (HP1) paralog Rhino. Through cross-species high-throughput yeast-two-hybrid screening, we identified three distinct evolutionary protein interaction trajectories across ~40 million years of Drosophila evolution. While several protein interactions are fully conserved, indicating functional conservation despite rapid amino acid-sequence change, other interactions are preserved through coevolution and were detected only between proteins within or from closely related species. We also identified species-restricted protein interactions, revealing insight into the mechanistic diversity and ongoing molecular innovation in Drosophila piRNA production. In sum, our analyses reveal principles of interaction evolution in an adaptively evolving protein–protein interaction network, and support intermolecular interaction innovation as a central molecular mechanism of evolutionary adaptation in protein-coding genes.